Why the study?
Elevated Lp(a) is an established causal risk factor for atherosclerotic cardiovascular disease that may contribute to residual risk during LDL-C-lowering therapy.
Case Report (n=1)
No
This five-year serial angiographic case report illustrates recurrent coronary events in distinct vascular territories alongside persistent severe Lp(a) elevation despite LDL-C reduction, highlighting the multifactorial nature of residual cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Recurrent events despite LDL-C 0.71 mmol/L highlight Lp(a) residual risk; single case leaves open Lp(a)-specific therapies.
Background Elevated lipoprotein(a) [Lp(a)] is an established causal risk factor for atherosclerotic cardiovascular disease and may contribute to residual risk. However, a single case cannot establish that Lp(a) caused recurrent events. Case presentation A man aged 65 years in 2026 with hypertension and type 2 diabetes experienced four coronary events between December 2021 and June 2026. Serial angiography documented severe first diagonal branch (D1) stenosis treated with a drug-coated balloon in 2021, total occlusion of the second obtuse marginal branch (OM2) treated with a drug-coated balloon in 2022, approximately 95% mid-right coronary artery (RCA) stenosis treated with a drug-eluting stent in 2023, and a new distal RCA occlusion causing inferior-posterior ST-segment elevation myocardial infarction (STEMI) in 2026. The previously implanted RCA stent remained patent during the 2026 event. Lp(a), measured by immunoturbidimetry at the same clinical laboratory, was 592, 899, 967, and 1,032 mg/L at the 2021, 2022, 2023, and June 2026 assessments, respectively, and 980 mg/L at stable follow-up in August 2026. LDL-C was 3.51 mmol/L in 2021, 1.14 mmol/L during the June 2026 STEMI, and 0.71 mmol/L at stable follow-up in August 2026. ApoB was not measured during the June 2026 admission. Conclusion This case documents recurrent coronary events in different territories alongside persistently marked Lp(a) elevation. Lp(a) may have contributed to residual risk, but prior LDL-C exposure, diabetes, hypertension, treatment intensity, adherence, and measurement variability are important alternative or additional explanations.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a case report in Recurrent coronary artery disease with persistently elevated lipoprotein(a) (n=1). Persistently elevated lipoprotein(a) during LDL-C-lowering therapy (evolocumab and statins) was evaluated on Recurrent coronary events documented by serial coronary angiography.
Synapse has enriched 10 related papers. Consider them for comparative context: